NKGen Biotech, Inc.

Biological Products, (No Diagnostic Substances)·SANTA ANA, CA

CEO

Song Paul Y.

CFO

Graf James A

Summary Financials

Revenue

$77,000

FY 2023

Adj. EBITDA

-$28.5M

-37068.8% margin

FY 2024

Net Income

-$83.0M

-107732.5% margin

FY 2024

EPS (Diluted)

-$5.38

FY 2024

Stock Price

—

52W Range

—

P/E Ratio

—

Market Cap

—

Cash

$26,000

FY 2024

Total Debt

—

Net Cash

$26,000

FY 2023

Enterprise Value

—

Debt / EBITDA

0.0x

FY 2023

EV / EBITDA

—

Employees

—

Revenue

$77,000

FY 2023

Adj. EBITDA

-$28.5M

-37068.8% margin

FY 2024

Net Income

-$83.0M

-107732.5% margin

FY 2024

EPS (Diluted)

-$5.38

FY 2024

Stock Price

—

52W Range

—

P/E Ratio

—

Market Cap

—

Cash

$26,000

FY 2024

Total Debt

—

Net Cash

$26,000

FY 2023

Enterprise Value

—

Debt / EBITDA

0.0x

FY 2023

EV / EBITDA

—

Employees

—